BRCA2 and familial pancreatic carcinoma: In the adjuvant setting, pancreatic cancer patients with germline BRCA1 and BRCA2 mutations who received adjuvant chemotherapy that included platinum drugs had a median survival of 31 months compared with 17.8 months for patients who received non-platinum adjuvant chemotherapy and 9.3 months in patients who had no chemotherapy [45].